The global genetic testing market size was estimated to be USD 18.24 billion in 2023 and is expected to reach at USD 60.1 billion by 2033 with a CAGR of 11.45 % during the forecast period 2023-2033. Increasing prevalence of genetic disorders, rising awareness of new-born screening tests, growing research & development activities, surge in technological advancements, increase in development of customized testing kits, rising focus by governments to create awareness regarding genetic tests, growing funding for research, surge in launch of innovative products, and increasing product approvals by U.S. Food and Drug Administration (FDA) are some of the key factors boosting the market growth.
Surge in launch of innovative products is predicted to boost the market growth during the forecast period. For instance, in July 2021, Avellino Labs has introduced AvaGen, a genetic eye test, in the United States, aimed at assessing the potential risk of keratoconus and other corneal dystrophies in patients.
By Disease, Cancer was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising prevalence of cancer such as lungs cancer, breast cancer, & bowel cancer and increasing launch of testing products. For instance, in March 2022, In Europe, Illumina, a genome sequencing company, has released a cancer test that examines a diverse array of tumor genes in a single tissue sample. This test has the potential to assist individuals with rare diseases in finding suitable treatment options. Additionally, Sickle cell anemia is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of anemia and increasing launch of advanced testing kits by market players.
By Product, Consumables was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising presence of market players providing consumables & offer a wide range of products in reagents and accessories and surge in continuous & repetitive usage of consumables during the process. Additionally, software & service is predicted to grow at fastest CAGR during the forecast period owing to the growing strategic initiatives by Contract Research Organizations (CROs), escalating range of services in genetic testing, increasing investment by market players, and surge in launch of advanced software. For instance, in August 2022, Thermo Fisher Scientific has introduced a CE-IVD (IVDD) next-generation sequencing test and analysis software, with the aim of broadening the availability of precise oncology biomarker testing in the field.
By Technology, Next-generation sequencing was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising genome mapping programs, growing healthcare expenditure, increasing technological advancements, surge in applications of next-generation sequencing, rising adoption of DNA sequencing technologies for the identification & characterization of cancer types & genetic disorders, and growing launch of advanced testing. For instance, in March 2022, ARUP has enhanced the speed and accuracy of their next-generation sequencing (NGS) tests through the introduction of Rio, an advanced bioinformatics pipeline and analytics platform. Additionally, Array technology is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of cancer, growing adoption of DNA-based array technology in genetic disease diagnosis & personalized medicine.
By Application, Diagnostic testing was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the growing prevalence of chronic diseases, rising geriatric population, surge in demand for the diagnostic testing, and increasing product approvals by regulatory bodies. For instance, in May 2020, The FDA has approved the BRACAnalysis CDx test as a companion diagnostic, according to Myriad Genetics, Inc. This test assists in identifying patients with high-risk early-stage breast cancer, specifically those with germline BRCA-mutated (gRBCAm), HER2 negative cancer, who may gain advantages from the medication Lynparza® (olaparib). Additionally, prenatal & newborn testing is predicted to grow at fastest CAGR during the forecast period owing to the rising prenatal & newborn testing, increasing screening in the developed regions, growing adoption of non-invasive testing.
By End-user, Hospitals and clinics was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the increasing adoption of mandatory newborn screening for genetic disorders, growing prevalence of cancer, rising capacity of hospitals and clinics, and surge in adoption of telehealth & in-house hospital services. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to rising demand for diagnostic testing and increasing partnerships and collaboration within market players. For instance, in January 2020, ARCHIMED Life has formed a strategic partnership with amides Holding GmbH to enhance and enhance the availability of specialized diagnostic services for genetic, biochemical, and biomarker testing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for diagnostic testing, rising prevalence of genetic disorders, growing development of technologically advanced diagnostic techniques, and surge in healthcare infrastructure, increasing government funding for research & development activities, rising demand for personalized genetic testing services, and growing product approvals by the US Food and Drug Administration (FDA). For instance, in October 2021, F. Hoffmann-La Roche Ltd has introduced the AVENIO Tumor Tissue CGP Kit, an extensive genomic profiling kit designed to increase the accessibility of personalized cancer research. This kit allows for comprehensive genomic profiling of solid tumors using formalin-fixed paraffin-embedded (FFPE) tissue samples. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of innovative laboratory techniques, rising demand of DNA sequencing for rapid investigation & diagnosis of chronic disorders, surge in cost effectiveness of genetic testing techniques, increasing awareness about genetic disorders, and growing expansion for development of gene products. For instance, in May 2020, The development of a new Good Manufacturing Practices (GMP) facility in Shiga, Japan, has been completed by Takara Bio USA, Inc. This facility is dedicated to the production of gene and cell therapy products.
Surge in launch of innovative products is predicted to boost the market growth during the forecast period. For instance, in July 2021, Avellino Labs has introduced AvaGen, a genetic eye test, in the United States, aimed at assessing the potential risk of keratoconus and other corneal dystrophies in patients.
By Disease, Cancer was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising prevalence of cancer such as lungs cancer, breast cancer, & bowel cancer and increasing launch of testing products. For instance, in March 2022, In Europe, Illumina, a genome sequencing company, has released a cancer test that examines a diverse array of tumor genes in a single tissue sample. This test has the potential to assist individuals with rare diseases in finding suitable treatment options. Additionally, Sickle cell anemia is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of anemia and increasing launch of advanced testing kits by market players.
By Product, Consumables was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising presence of market players providing consumables & offer a wide range of products in reagents and accessories and surge in continuous & repetitive usage of consumables during the process. Additionally, software & service is predicted to grow at fastest CAGR during the forecast period owing to the growing strategic initiatives by Contract Research Organizations (CROs), escalating range of services in genetic testing, increasing investment by market players, and surge in launch of advanced software. For instance, in August 2022, Thermo Fisher Scientific has introduced a CE-IVD (IVDD) next-generation sequencing test and analysis software, with the aim of broadening the availability of precise oncology biomarker testing in the field.
By Technology, Next-generation sequencing was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the rising genome mapping programs, growing healthcare expenditure, increasing technological advancements, surge in applications of next-generation sequencing, rising adoption of DNA sequencing technologies for the identification & characterization of cancer types & genetic disorders, and growing launch of advanced testing. For instance, in March 2022, ARUP has enhanced the speed and accuracy of their next-generation sequencing (NGS) tests through the introduction of Rio, an advanced bioinformatics pipeline and analytics platform. Additionally, Array technology is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of cancer, growing adoption of DNA-based array technology in genetic disease diagnosis & personalized medicine.
By Application, Diagnostic testing was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the growing prevalence of chronic diseases, rising geriatric population, surge in demand for the diagnostic testing, and increasing product approvals by regulatory bodies. For instance, in May 2020, The FDA has approved the BRACAnalysis CDx test as a companion diagnostic, according to Myriad Genetics, Inc. This test assists in identifying patients with high-risk early-stage breast cancer, specifically those with germline BRCA-mutated (gRBCAm), HER2 negative cancer, who may gain advantages from the medication Lynparza® (olaparib). Additionally, prenatal & newborn testing is predicted to grow at fastest CAGR during the forecast period owing to the rising prenatal & newborn testing, increasing screening in the developed regions, growing adoption of non-invasive testing.
By End-user, Hospitals and clinics was the highest revenue-grossing segment in the global genetic testing market in 2022 owing to the increasing adoption of mandatory newborn screening for genetic disorders, growing prevalence of cancer, rising capacity of hospitals and clinics, and surge in adoption of telehealth & in-house hospital services. Additionally, Diagnostic laboratories is predicted to grow at fastest CAGR during the forecast period owing to rising demand for diagnostic testing and increasing partnerships and collaboration within market players. For instance, in January 2020, ARCHIMED Life has formed a strategic partnership with amides Holding GmbH to enhance and enhance the availability of specialized diagnostic services for genetic, biochemical, and biomarker testing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for diagnostic testing, rising prevalence of genetic disorders, growing development of technologically advanced diagnostic techniques, and surge in healthcare infrastructure, increasing government funding for research & development activities, rising demand for personalized genetic testing services, and growing product approvals by the US Food and Drug Administration (FDA). For instance, in October 2021, F. Hoffmann-La Roche Ltd has introduced the AVENIO Tumor Tissue CGP Kit, an extensive genomic profiling kit designed to increase the accessibility of personalized cancer research. This kit allows for comprehensive genomic profiling of solid tumors using formalin-fixed paraffin-embedded (FFPE) tissue samples. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of innovative laboratory techniques, rising demand of DNA sequencing for rapid investigation & diagnosis of chronic disorders, surge in cost effectiveness of genetic testing techniques, increasing awareness about genetic disorders, and growing expansion for development of gene products. For instance, in May 2020, The development of a new Good Manufacturing Practices (GMP) facility in Shiga, Japan, has been completed by Takara Bio USA, Inc. This facility is dedicated to the production of gene and cell therapy products.
Segmentation: Genetic Testing Market Report 2022 - 2033
Genetic Testing Market Analysis & Forecast by Disease 2022 - 2033 (Revenue USD Bn)
- Sickle Cell Anemia
- Alzheimer's Disease
- Rare Diseases
- Cancer
- Cystic Fibrosis
- Huntington's Disease
- Thalassemia
- Duchenne Muscular Dystrophy
- Others
Genetic Testing Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Software & Services
- Consumables
- Equipment
Genetic Testing Market Analysis & Forecast by Technology 2022 - 2033 (Revenue USD Bn)
- PCR-based Testing
- Next Generation Sequencing
- FISH
- Array Technology
- Others
Genetic Testing Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Prenatal Testing
- New-born Screening
- Carrier Testing
- Diagnostic Testing
- Predictive and Presymptomatic Testing
- Others
Genetic Testing Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Diagnostic Laboratories
- Hospitals & Clinics
- Others
Genetic Testing Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Genetic Testing Market: Disease Estimates & Trend Analysis
8. Genetic Testing Market: Product Estimates & Trend Analysis
9. Genetic Testing Market: Technology Estimates & Trend Analysis
10. Genetic Testing Market: Application Estimates & Trend Analysis
11. Genetic Testing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Genetic Testing Market
14. Europe Global Genetic Testing Market
15. Asia Pacific Global Genetic Testing Market
16. Latin America Global Genetic Testing Market
17. MEA Global Genetic Testing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Illumina Inc.
- Circle DNA
- Amgen Inc.
- Myriad Genetics Inc.
- MyDNA
- AncestryDNA
- Tellmegen
- MyHeritage Ltd.
- Igenomix
- 24 genetics
- Mapmygenome
- VitaGen
- Helix OpCo LLC
- Everly Well
- 23andme
- Color Genomics Inc.
- Beyond Nutrition Health and Wellness Services DMCC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 18.24 Billion |
| Forecasted Market Value ( USD | $ 60.1 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
